Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06991114 · ClinicalTrials.gov registry record · Phase 2
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
A Phase 2 study of Scleroderma and Rheumatoid Arthritis (RA), sponsored by Artiva Biotherapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 20
- Study locations
NCT06991114: Recruiting Phase 2 study of Scleroderma and Rheumatoid Arthritis (RA), sponsored by Artiva Biotherapeutics.
NCT06991114 is a Phase 2 study of Scleroderma and Rheumatoid Arthritis (RA) that is actively recruiting participants, run by Artiva Biotherapeutics. The registered enrollment target is 90 participants, below the 399-participant average among 23 other Scleroderma trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06991114, a Phase 2 study of Scleroderma and Rheumatoid Arthritis (RA), is actively recruiting participants, sponsored by Artiva Biotherapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.
Primary Outcome
Dose Limiting toxicities assessed in a incrementing dose design.
Conditions Studied
Interventions
- DRUG Allogeneic NK Cells
Study Locations (20)
Texas
- Artiva Investigational Site Arlington - Arlington
- Artiva Investigational Site Katy - Katy
- Artiva Investigational Site Mesquite - Mesquite
- Artiva Investigational Site Woodland - Woodland
Other
- Artiva Investigational Site Sofia - Sofia
- Artiva Investigational Site Marseille - Marseille
- Artiva Investigational Site Montpellier - Montpellier
- Artiva Investigational Site Toulouse - Toulouse
Florida
- Artiva Investigational Site Aventura - Aventura
- Artiva Investigational Site Jupiter - Jupiter
- Artiva Investigational Site Plantation - Plantation
California
- Artiva Investigational Site Covina - Covina
- Artiva Investigational Site Los Alamitos - Los Alamitos
North Carolina
- Artiva Investigational Site Charlotte - Charlotte
- Artiva Investigational Site Charlotte - Charlotte
Alabama
- Artiva Investigational Site Tuscaloosa - Tuscaloosa
Arizona
- Artiva Investigational Site Phoenix - Phoenix
Illinois
- Artiva Investigational Site Willowbrook - Willowbrook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2025-07-09 |
| Est. Completion | 2029-01 |
| Phase | Phase 2 |
What NCT06991114 shows while recruiting
NCT06991114 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 399-participant average among 23 other Scleroderma trials with a reported enrollment target (77% lower).
The record links to 9 conditions, with Scleroderma appearing as the primary indexed condition, and to 1 intervention - of which Allogeneic NK Cells is the first listed.
NCT06991114 names 20 study sites across 10 states, led by Texas, Other, Florida.
Frequently Asked Questions
What is clinical trial NCT06991114 about?
NCT06991114 is a clinical study titled "AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.". A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.
What is the current status of trial NCT06991114?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2025-07-09. Estimated completion is 2029-01.
What conditions does trial NCT06991114 study?
This clinical trial studies the following conditions: Scleroderma, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Myositis, Sjogren Syndrome.
What interventions are being tested in trial NCT06991114?
The interventions under investigation include: Allogeneic NK Cells (DRUG).
Who is sponsoring clinical trial NCT06991114?
This trial is sponsored by Artiva Biotherapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06991114 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Scleroderma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06991114's enrollment target sits among peer trials
90 10th of 23 higher than 14 of 23 other Scleroderma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Scleroderma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Platform Clinical Study for Conquering Scleroderma
RECRUITING · Phase 2
-
Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
RECRUITING · Phase 2
-
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
RECRUITING · Phase 2
-
Psychological Treatments for Scleroderma
COMPLETED · Phase 2
-
Rheumatology Diet Study
RECRUITING
-
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI